Company profile
UK company 08295004, incorporated on 15 November 2012.
Stem Cells | Alzheimers Disease | Dementia Research | Stratastem
StrataStem, innovative stem cell research and alzheimers disease. Developing intelligent drug screening platforms to identify therapeutics for alzheimers disease.
Company number 08295004
Financial period: 1 Dec 2023 to 30 Nov 2024
Reference milestones and recent Companies House filing stream events.
TM01 | Transaction MzUzNjY2NjYwMWFkaXF6a2N4
Published 03 Aug 2026 10:54
Company registered at Companies House
Stratastem develops therapeutics for Alzheimer's disease based on neural stem cells, as well as diagnostics for the disease that detect changes in neuronal pathology.
Biotech Start-up
Biotech Start-up
1 Apr 2023 to 31 Mar 2026
1 Jun 2020 to 30 Nov 2020
no public description
1 Jun 2019 to 31 Mar 2021
Recent advances have deepened our understanding of the pathology of Alzheimer's disease and resulted in revised criteria, clinical trial assessment and disease management with a focus on early-stage manifestations of the disease. Using iPSC technology, StrataStem have derived pluripotent cells from clinically diagnosed fAD patients and differentiated thes...
